Leilei Xia, MD

Urology
Accepting new patients
Sees patients age 18 and up
Penn Urology Perelman
Make an appointmentCall 215-662-2891
Headshot of Leilei Xia, MD
Penn Medicine Provider

About me

  • Assistant Professor of Surgery at the Hospital of the University of Pennsylvania

My education and training

  • Medical School: Anhui Medical University
  • Residency: University of Pennsylvania Health System
  • Fellowship: USC Medical Center

Spoken languages

English
English

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Xia is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Ribal MJ, Rosenberg J, Ajami T, Vilaseca A, Xia L, Sternschuss M, Schuckman AK Advancing perioperative treatment options for localized muscle-invasive bladder cancer: A step forward , American Society of Clinical Oncology Educational Book, 45(3): 2025,e472822

Doshi C, Zahir M, Dadabhoy A, Xia L, Miranda G, Cai J, Daneshmand S Evaluation of the potential impact of care fragmentation on survival outcomes in muscle invasive bladder cancer patients , Urologic Oncology: Seminars & Original Investigations, 43(3 Suppl): 2025,44

Davis R, Xia L, Miranda G, Cai J, Daneshmand S Outcomes following neoadjuvant cisplatin-based chemotherapy and cystectomy for muscle invasive urothelial carcinoma with concomitant carcinoma in situ , Urologic Oncology: Seminars & Original Investigations, 43(3 Suppl): 2025,18-19

Xia L, Dadabhoy A, Molina LS, Wood E, Lee Y, Miranda G, Cai J, Djaladat H, Schuckman A, Daneshmand S Level of nodal metastasis in patients undergoing radical cystectomy and lymphadenectomy: Is there a role of extended lymphadenectomy in the post-S1011 era? , Urologic Oncology: Seminars & Original Investigations, 43(3 Suppl): 2025,19

Doshi C, Dadabhoy A, Moghaddam FS, Wood E, Xia L, Daneshmand S Assessing the diagnostic utility of cxbladder monitor as an alternative to surveillance cystoscopy , Urologic Oncology: Seminars & Original Investigations, 43(3 Suppl): 2025,94

Doshi C, Dadabhoy A, Ladi-Seyedian S, Xia L, Schuckman A, Daneshmand S Alopecia as an uncommon side effect of single postoperative instillation of gemcitabine in patients with non-muscle invasive urothelial carcinoma of the bladder: A multi-institution experience , Urologic Oncology: Seminars & Original Investigations, 43(3 Suppl): 2025,93-94

Doshi C, Zahir M, Escobar D, Xia L, Daneshmand S Complications after transurethral resection of bladder tumor: Findings from the 2022 ACS NSQIP database , Journal of Clinical Oncology, 43(Suppl 5): 2025

Doshi C, Zahir M, Dadabhoy A, Escobar D, Xia L, Daneshmand S Serum tumor markers for muscle-invasive bladder cancer in clinical practice: A narrative review , Cancers (Basel), 17(5): 2025,728

Ku J, Doshi C, Dadabhoy A, Xia L, Daneshmand S Clinicopathological variations between early and late recurrence in bladder cancer post-radical cystectomy , Journal of Clinical Oncology, 43(Suppl 5): 2025

Zahir M, Doshi C, Escobar D, Xia L, Miranda G, Cai J, Schuckman AK, Djaladat H, Daneshmand S Evaluating the survival benefits of adjuvant immunotherapy in muscle-invasive urothelial carcinoma: A real-world experience , Journal of Clinical Oncology, 43(Suppl 5): 2025